DR info

臨床試験数 : 10 / 薬物数 : 13 - (DrugBank : 4) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Cannabidiol
   Anne Comi, MD
      2019   Phase 2   NCT04447846   United States;
      2014   Phase 1/Phase 2   NCT02332655   United States;
Crema de rapamicina al y excipientes
   Instituto Científico y Tecnológico de Navarra
      2011   -   EUCTR2010-024078-20-ES   Spain;
Crema placebo (excipiente)
   Instituto Científico y Tecnológico de Navarra
      2011   -   EUCTR2010-024078-20-ES   Spain;
Everolimus
   Baylor College of Medicine
      2014   Phase 2   NCT01997255   United States;
Haemoblock
   Center for Vascular Pathology, Moscow
      2020   Phase 4   NCT04999618   Russian Federation;
Modified Atkins diet
   Johns Hopkins University
      2006   Phase 1   NCT00639730   United States;
Preservative free artificial tear gel.
   Wills Eye
      2012   Phase 1   NCT01533376   United States;
QLS-101ophthalmic solution
   Qlaris Bio, Inc.
      2021   Phase 2   NCT04947124   United States;
Rapamicina tópica al y excipiente
   Instituto Científico y Tecnológico de Navarra
      2011   -   EUCTR2010-024078-20-ES   Spain;
Sirolimus
   Anne Comi, MD
      2017   Phase 2/Phase 3   NCT03047980   United States;
Timolol
   Wills Eye
      2012   Phase 1   NCT01533376   United States;
Topical Rapamycin
   Clinica Universidad de Navarra, Universidad de Navarra
      2011   Phase 2   NCT02080624   Spain;